Sialic Acid Binding Immunoglobulin-like Lectins
Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3
Aviceda; AVD-104; geographic atrophy; dry AMD; Phase 2b; SIGLEC trial; Izervay; avacincaptad pegol; clinical trial failure; Phase 3 prospects